.jpg)
10 hours ago
3
Article content
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 12 assays specific to brain and peripheral Tau isoforms | NULISA™ data to be presented in over 11 scientific sessions and 25 posters at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026)
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Fremont, CA, March 17, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (“Alamar”), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of the NULISAseq Neuro 220 Panel with multiplexed measurement of 220 biomarkers from a single sample while maintaining ultra-high sensitivity and high specificity. The panel expands on the flagship NULISAseq CNS Disease Panel 120 and features new biomarker content developed with support from MJFF for Parkinson’s Research as well as a substantial collection of highly selective Tau protein assays targeting both brain-derived and peripheral isoforms of total tau and the phosphorylated species; pTau217, pTau181, pTau205, pTau212, and pTau231. We believe this represents the largest suite of Tau assays available in a single panel and demonstrates the ability of the NULISA™ chemistry to distinguish between organ specific isoforms as well as a variety of post translational modifications.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“We are proud to support Alamar as they work to develop highly sensitive assays for several known and emerging biomarkers important in Parkinson’s disease research,” said Nicole Polinski, PhD, Director, Research Programs at MJFF. “We believe these assays will help the research community to better understand the progression of disease and expedite the development of diagnostic and prognostic signatures.”
Article content
Article content
“This launch reflects our continued innovation in precision proteomics, expanding our neurodegenerative disease panel to better capture the molecular complexity of diseases such as Alzheimer’s and Parkinson’s,” said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. “We’re grateful for The Michael J. Fox Foundation’s trust and partnership, and for their collaboration in advancing Parkinson’s novel biomarker content for the research community.”
Article content
The NULISAseq Neuro 220 Panel raises the standard for neurodegenerative disease research, applicable to a broad range of neurological disorders including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, frontotemporal dementia, Lewy body dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington’s disease, vascular dementia, gliomas and traumatic brain injury. The panel’s ultra-high sensitivity and high specificity ensure compatibility with non-invasive sample collection devices and supports pre-symptomatic detection, while automated workflows using the ARGO™ HT System deliver exceptional reproducibility and ease of use, facilitating the analysis of disease heterogeneity, detection of co-pathologies, and the identification of prognostic or therapeutic response signatures across clinical cohorts.
English (US)